Results 141 to 150 of about 4,801,388 (251)
Discover OncologyOvarian cancer ranks sixth as the most common cancer and fifth as the most deadly malignancy among women worldwide. In addition, it places third among the most common gynecological cancers. Which proves that it is a significant medical problem worldwide.
Weronika Anna Jurgiel +2 more
doaj +1 more source
Activation of Metal Complexes With Ultrasound Waves for Targeted Anticancer Therapy
Angewandte Chemie International Edition, EarlyView.Ultrasound enables non‐invasive activation of metal‐based therapeutics deep within tumors. Acoustic cavitation can drive sonodynamic reactive oxygen species generation or mechanochemical metal–ligand bond dissociation, enabling controlled release of bioactive payloads.
Félix Grosjean +3 more
wiley +1 more source
Serum Lipidome Profiling Reveals a Distinct Signature of Ovarian Cancer in Korean Women
Background: Distinguishing ovarian cancer from other gynecological malignancies is crucial for patient survival yet hindered by non-specific symptoms and limited understanding of ovarian cancer pathogenesis.
Cho, Chi-Heum +10 more
core +1 more source
The Role of miRNAs in Chicken Immune Regulation and Prospects for Disease‐Resistant Breeding
Animal Research and One Health, EarlyView.A schematic workflow illustrating the screening of disease‐resistant miRNAs and the generation of miRNA‐based disease‐resistant chickens via PGC‐mediated germline genome editing. ABSTRACT MicroRNAs (miRNAs) are emerging as pivotal regulators of the immune system, playing a decisive role in shaping disease resistance in chicken.
Qiangzhou Wang +10 more
wiley +1 more source
How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU
British Journal of Clinical Pharmacology, EarlyView.The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley +1 more source
Outcomes From Opportunistic Salpingectomy for Ovarian Cancer Prevention.
JAMA Netw Open, 2022 Hanley GE +7 more
europepmc +1 more source
Efficacy, safety and cost‐effectiveness of CAR‐T therapy
British Journal of Clinical Pharmacology, EarlyView.CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher +7 more
wiley +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims This work aimed to contextualize glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists safety and efficacy regarding weight management (WM); we analysed Food and Drug Administration (FDA) Medical Reviews to analyse 14 medications using patient‐exposure year normalization and ...
Aishwarya Prasad +4 more
wiley +1 more source
Artificial intelligence in ovarian cancer prevention and control: a brief review of detection, treatment, and equity (2021-2026). [PDF]
Front OncolHuang Z, Wei B, Shen Y.
europepmc +1 more source
Regulatory harmonization: Evolution, globalization and future directions
British Journal of Clinical Pharmacology, EarlyView.Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm +2 more
wiley +1 more source